These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 9225305

  • 1. [3H]raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects.
    Dean B, Pavey G, Opeskin K.
    Neuropharmacology; 1997 Jun; 36(6):779-86. PubMed ID: 9225305
    [Abstract] [Full Text] [Related]

  • 2. Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims.
    Ruiz J, Gabilondo AM, Meana JJ, García-Sevilla JA.
    Psychopharmacology (Berl); 1992 Jun; 109(4):410-4. PubMed ID: 1365855
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY.
    Brain Res; 1995 May 29; 681(1-2):109-16. PubMed ID: 7552267
    [Abstract] [Full Text] [Related]

  • 4. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects.
    Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, Tamminga CA.
    Neuroreport; 1996 Aug 12; 7(12):1945-8. PubMed ID: 8905699
    [Abstract] [Full Text] [Related]

  • 5. [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.
    Xu J, Hassanzadeh B, Chu W, Tu Z, Jones LA, Luedtke RR, Perlmutter JS, Mintun MA, Mach RH.
    Synapse; 2010 Jun 12; 64(6):449-59. PubMed ID: 20175227
    [Abstract] [Full Text] [Related]

  • 6. Persistent, specific and dose-dependent effects of toluene exposure on dopamine D2 agonist binding in the rat caudate-putamen.
    Hillefors-Berglund M, Liu Y, von Euler G.
    Toxicology; 1995 Jun 26; 100(1-3):185-94. PubMed ID: 7624876
    [Abstract] [Full Text] [Related]

  • 7. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia.
    Marzella PL, Hill C, Keks N, Singh B, Copolov D.
    Biol Psychiatry; 1997 Oct 15; 42(8):648-54. PubMed ID: 9325557
    [Abstract] [Full Text] [Related]

  • 8. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia.
    Dean B, Pavey G, Scarr E, Goeringer K, Copolov DL.
    Life Sci; 2004 May 07; 74(25):3115-31. PubMed ID: 15081577
    [Abstract] [Full Text] [Related]

  • 9. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P, Niznik HB, Guan HC.
    Arch Gen Psychiatry; 1990 Dec 07; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes.
    Hall H, Wedel I, Halldin C, Kopp J, Farde L.
    J Neurochem; 1990 Dec 07; 55(6):2048-57. PubMed ID: 1977888
    [Abstract] [Full Text] [Related]

  • 11. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients.
    Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, Kleinman JE.
    Biol Psychiatry; 1994 Dec 15; 36(12):827-35. PubMed ID: 7893846
    [Abstract] [Full Text] [Related]

  • 12. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, Sedvall G.
    Arch Gen Psychiatry; 1990 Mar 15; 47(3):213-9. PubMed ID: 1968328
    [Abstract] [Full Text] [Related]

  • 13. Specific [3H]raclopride binding to neostriatal dopamine D2 receptors: role of disulfide and sulfhydryl groups.
    Reader TA, Molina-Holgado E, Lima L, Boulianne S, Dewar KM.
    Neurochem Res; 1992 Aug 15; 17(8):749-59. PubMed ID: 1379349
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
    Tarazi FI, Florijn WJ, Creese I.
    Neuroscience; 1997 Jun 15; 78(4):985-96. PubMed ID: 9174067
    [Abstract] [Full Text] [Related]

  • 15. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
    Seeman P, Van Tol HH.
    J Neurochem; 1995 Mar 15; 64(3):1413-5. PubMed ID: 7861175
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride.
    Antonini A, Leenders KL.
    Ann N Y Acad Sci; 1993 Sep 24; 695():81-5. PubMed ID: 8239318
    [Abstract] [Full Text] [Related]

  • 17. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.
    Primus RJ, Thurkauf A, Xu J, Yevich E, McInerney S, Shaw K, Tallman JF, Gallagher DW.
    J Pharmacol Exp Ther; 1997 Aug 24; 282(2):1020-7. PubMed ID: 9262371
    [Abstract] [Full Text] [Related]

  • 18. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
    Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
    Brain Res; 1997 Aug 08; 765(1):7-12. PubMed ID: 9310388
    [Abstract] [Full Text] [Related]

  • 19. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Långström B.
    Neurology; 1996 May 08; 46(5):1430-6. PubMed ID: 8628494
    [Abstract] [Full Text] [Related]

  • 20. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
    Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK.
    J Neurol Sci; 1995 Oct 08; 132(2):156-61. PubMed ID: 8543941
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.